Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH
Author Information
Author(s): P.N. Brawn, E.H. Johnson, V.O. Speights, M. Riggs, M. Lind, N. Bell
Primary Institution: Veterans Administration Medical Center, Texas A&M University College of Medicine
Hypothesis
How does the long-term survival of patients with stage A prostate carcinoma compare to those with atypical hyperplasia/adenosis and benign prostatic hyperplasia?
Conclusion
Patients with stage A prostate carcinoma have similar survival rates to those with atypical hyperplasia/adenosis and benign prostatic hyperplasia, while stage A2 carcinoma is associated with worse survival.
Supporting Evidence
- Stage A1 prostate carcinoma had similar survival rates to benign prostatic hyperplasia.
- Stage A2 prostate carcinoma was associated with significantly worse survival.
- Therapy was associated with survival in stage A1 patients but not in stage A2 or atypical hyperplasia/adenosis patients.
Takeaway
This study found that men with early-stage prostate cancer often live just as long as men with non-cancerous prostate conditions.
Methodology
The study followed 134 patients diagnosed with stage A prostate carcinoma and compared their survival with a control group of patients with benign prostatic hyperplasia.
Potential Biases
Potential selection bias in therapy assignment and follow-up.
Limitations
The study only included patients from a single medical center and may not be generalizable to other populations.
Participant Demographics
Mean ages were 70 for stage A1, 75 for stage A2, and 68 for atypical hyperplasia/adenosis.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website